Clin2
NCT07224360Possibly a fitRecruiting

Safety of a new drug for sickle cell pain

Sickle Cell Disease

Part of Blood & lymphatic, Genetic & congenital clinical trials.

This study tests a new medicine called anumigilimab to see if it is safe for people with sickle cell disease. The study focuses on those who have had pain crises recently, to help manage and prevent them.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
63 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 years or older.
  • You must have sickle cell disease of any type.
  • You must have had 1 to 12 pain crises in the past 12 months that required a visit to a medical facility and pain medication.
  • You must be on a stable dose of hydroxyurea (if you take it) for at least 30 days, or have stopped or refused it.
  • You must not have a very low white blood cell count (below 2.5 x 10^9 cells per liter).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06725550Recruiting
Acupuncture for pain in sickle cell disease

This trial tests whether adding acupuncture to standard pain treatments can help manage pain in people with sickle cell disease. It involves brain scans, questionnaires, and acupuncture sessions to see if this approach reduces pain and improves quality of life.

Cincinnati, Ohio
NCT04055818Recruiting· Phase 1
Testing three medicines for high-risk sickle cell disease

This Phase 1 study tests whether nicotinamide, oral tetrahydrouridine, and decitabine can help people with high-risk sickle cell disease. It is mainly a safety-and-dosing study, but it also looks for signs the medicines may improve disease-related problems.

Chicago, Illinois
NCT06975865Recruiting· Phase 3
Rilzabrutinib for sickle-cell disease pain episodes

This study tests an oral medicine called rilzabrutinib to see if it can reduce painful episodes in people with sickle-cell disease. It may be an option if you have regular pain crises and are looking for a new treatment.

Birmingham, Alabama
NCT06439082Recruiting· Phase 3
Crizanlizumab for sickle cell pain crises

This trial tests whether crizanlizumab can reduce painful sickle cell crises (called vaso-occlusive crises or VOCs) in people with sickle cell disease who have frequent crises. It may be an option for those who still have crises despite current treatments.

Birmingham, Alabama
NCT07282210Recruiting· Phase 2
New medicine for sickle cell hemolysis

This trial tests a new medicine (SIL-8301) to help control red blood cell breakdown (hemolysis) in people with sickle cell disease. It is for those who are already taking hydroxyurea and have had few pain crises but still have complications from hemolysis.

Toronto, Ontario
NCT06635902Recruiting· Phase 2
Citrulline for sickle cell pain crisis

This trial tests if an intravenous medication called L-citrulline can help treat pain crises in children and young adults with sickle cell disease. Participants receive either the study drug or a placebo while in the hospital for a severe pain episode.

Washington D.C., District of Columbia

Hear when a new Sickle Cell Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.